8-K: Acrivon Therapeutics Prioritizes Endometrial Cancer Program Following Promising ACR-368 Data; Provides Corporate Update

Acrivon Therapeutics focuses on endometrial cancer and ACR-2316, citing encouraging ACR-368 data and deprioritizes ovarian and bladder cancer programs.

Summary

• Acrivon Therapeutics announced a corporate update on March 25, 2025, highlighting its strategic focus on the ACR-368 program in endometrial cancer and the ACR-2316 program in advanced solid tumors.
• The company presented interim data from the ACR-368 trial in Oncosignature-positive (BM+) endometrial cancer patients, showing a 35% confirmed overall response rate (ORR) and an 80% disease control rate (DCR).
• In BM+ patients with tumors refractory to the last prior line of therapy, ACR-368 demonstrated a 33% ORR and a 75% DCR.
• Preliminary analyses of BMpatients treated with ACR-368 plus ultra-low dose gemcitabine (LDG) showed a confirmed ORR of approximately 13%.
• Based on these results, the company is prioritizing endometrial cancer as its first potential registrational opportunity for ACR-368, estimating approximately 27,000 U.S. patients annually in the second-line setting alone.
• Acrivon is deprioritizing ovarian and bladder cancer programs due to increased competition, a smaller market opportunity, and lower than predicted BM+ rate in bladder cancer.
• The ACR-2316 Phase 1 trial is ongoing, with initial clinical activity observed in a patient in Dose Level 3.
• The company believes its cash, cash equivalents, and short-term investments of $184.6 million as of December 31, 2024, will be sufficient to fund operations into 2027.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, driven by promising clinical data for ACR-368 in endometrial cancer and a focus on a high-potential market. The company's strong cash position and strategic prioritization of programs contribute to the positive sentiment. However, the deprioritization of other programs and the early stage of ACR-2316 temper the overall optimism.

Positives

• ACR-368 shows promising clinical activity in BM+ endometrial cancer patients, particularly those with refractory tumors.
• The OncoSignature appears to accurately identify patients whose tumors are sensitive to ACR-368, with 80% of BM+ patients demonstrating tumor shrinkage.
• The company is prioritizing endometrial cancer, which represents a significant commercial opportunity with a large unmet need.
• Initial clinical activity has been observed in the ACR-2316 Phase 1 trial.
• Acrivon has a strong cash position of $184.6 million, providing a runway into 2027.

Negatives

• The ORR of approximately 13% in BMpatients treated with ACR-368 plus LDG is comparable to the best ORR in the last prior line of therapy.
• Ovarian and bladder cancer programs are being deprioritized.
• The preliminary cash balance is subject to change as the consolidated financial statements for 2024 have not been finalized.

Risks

• The preliminary cash balance is subject to change.
• The success of ACR-368 depends on the ability to accurately identify OncoSignature-positive patients.
• The development of ACR-2316 is still in early stages, and its efficacy and safety need to be further evaluated.
• The company faces competition in the endometrial cancer market.

Future Outlook

The company believes its current cash position will be sufficient to fund operations into 2027. Acrivon continues pursuing registrational intent for ACR-368 in 2nd line BM+ patients and a confirmatory trial strategy in frontline.

Management Comments

• The company believes this supports significant LDG sensitization to ACR-368 in BMpatients.
• The company remains confident in its strategy based on emerging clinical data, competitive positioning given limited treatment options, and the strong commercial opportunity in both secondand front-line settings.

Industry Context

The focus on endometrial cancer aligns with the growing interest in targeted therapies and immunotherapies for this indication. The company's AP3 platform aims to personalize treatment by identifying patients most likely to respond to specific drugs. The deprioritization of ovarian and bladder cancer reflects the challenges in these competitive markets.

Comparison to Industry Standards

• The 35% ORR observed with ACR-368 in BM+ endometrial cancer patients compares favorably to the 10-12% ORR typically seen with chemotherapy in the second-line setting.
• The company's strategy of combining ACR-368 with anti-PD-1 therapy in the frontline setting is similar to other approaches being explored in endometrial cancer, such as the combination of carboplatin, paclitaxel, and pembrolizumab.
• The development of ACR-2316 as a WEE1/PKMYT1 inhibitor is in line with the industry's interest in targeting cell cycle checkpoints for cancer therapy; however, Acrivon is attempting to overcome the limitations of current WEE1 inhibitors through AP3-based proteome-wide SAR.

Stakeholder Impact

• Shareholders: The strategic focus on endometrial cancer and the promising clinical data for ACR-368 could positively impact shareholder value.
• Employees: The reallocation of resources to the endometrial cancer and ACR-2316 programs may affect employees working on the deprioritized programs.
• Patients: The development of ACR-368 could provide a new treatment option for patients with endometrial cancer, particularly those with OncoSignature-positive tumors.
• Customers: The company does not have any products on the market, so there is no immediate impact on customers.
• Suppliers: The company's research and development activities may generate demand for suppliers of laboratory equipment and services.
• Creditors: The company's strong cash position reduces the risk for creditors.

Next Steps

• The company plans to provide an update on the registrational intent trial and confirmatory trial design for ACR-368 in endometrial cancer in the second half of 2025.
• Acrivon will continue the Phase 1 dose escalation and expansion trial for ACR-2316.
• The company aims to nominate a development candidate for its cell cycle program in 2025.

Key Dates

Keywords

Acrivon Therapeutics, ACR-368, ACR-2316, Endometrial Cancer, OncoSignature, Clinical Trial, Phase 2, Phase 1, R&D, Precision Medicine